'Quiet revolution' may herald new RNA therapeutics

Jan 21, 2007

Scientists at the University of Oxford have identified a surprising way of switching off a gene involved in cell division. The mechanism involves a form of RNA, a chemical found in cell nuclei, whose role was previously unknown, and could have implications for preventing the growth of tumour cells.

RNA plays an important and direct role in the synthesis of proteins, the building blocks of our bodies. However, scientists have known for some time that not all types of RNA are directly involved in protein synthesis. Now, in research funded by the Wellcome Trust and the Medical Research Council, a team of scientists has shown that one particular type of RNA plays a key role in regulating the gene implicated in control of tumour growth. The research is published online today in Nature.

The Human Genome Project identified about 34,000 genes responsible for producing proteins. The remaining part – in fact, most of the genome – constituted what was considered to be "junk" DNA with no function. However, latest estimates show that this "junk" DNA produces around half a million varieties of RNA of unknown functions.

"There's been a quiet revolution taking place in biology during the past few years over the role of RNA," says Dr Alexandre Akoulitchev, a Senior Research Fellow at the University of Oxford. "Scientists have begun to see 'junk' DNA as having a very important function. The variety of RNA types produced from this "junk" is staggering and the functional implications are huge."

The particular form of RNA that has been of interest to Dr Akoulitchev's team is involved in regulation of the dihydrofolate reductase gene (DHFR), determining whether the gene is "on" or "off". The DHFR gene produces an enzyme that controls thymine production, necessary in rapidly dividing cells.

"Inhibiting the DHFR gene could help prevent the growth of neoplastic cancerous cells, ordinary cells which develop into tumour cells, such as in prostate cancer cells," explains Dr Akoulitchev. "In fact, the first anti-cancer drug, Methotrexate, acts by binding and inhibiting the enzyme produced by this gene."

Dr Akoulitchev believes that understanding how we can use the RNA to switch off or inhibit DHFR and other genes may have important therapeutic implications for developing new anti-cancer treatments.

Source: Wellcome Trust

Explore further: Computational tool translates complex data into simplified 2-dimensional images

add to favorites email to friend print save as pdf

Related Stories

The many faces of the bacterial defense system

Apr 30, 2013

Even bacteria have a kind of "immune system" they use to defend themselves against unwanted intruders – in their case, viruses. Scientists at the Helmholtz Center for Infection Research (HZI) in Braunschweig, ...

Team discovers how a protein finds its way

Apr 29, 2013

(Phys.org) —Proteins, the workhorses of the body, can have more than one function, but they often need to be very specific in their action or they create cellular havoc, possibly leading to disease.

Recommended for you

Preventing blood poisoning

May 17, 2013

Peptide molecules derived from the body's natural immune system can help boost the body's defence against life-threatening blood poisoning, joint University research has uncovered.

User comments : 0

More news stories

Heat-related deaths in Manhattan projected to rise

Residents of Manhattan will not just sweat harder from rising temperatures in the future, says a new study; many may die. Researchers say deaths linked to warming climate may rise some 20 percent by the 2020s, ...

Kinks and curves at the nanoscale

One of the basic principles of nanotechnology is that when you make things extremely small—one nanometer is about five atoms wide, 100,000 times smaller than the diameter of a human hair—they are going ...